Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 3, 1998, Pages 221-228

  Piotrovsky, Vladimir K ^a   Huang, May Lynn ^a   Van Peer, Achiel ^a   Langenaecken, Christine ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Population pharmacokinetics NONMEM; Vorozole

Indexed keywords

AROMATASE INHIBITOR; VOROZOLE;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DRUG ABSORPTION; DRUG DISTRIBUTION; FEMALE; GENDER; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOEPIDEMIOLOGY; POPULATION MODEL; PRIORITY JOURNAL; RACE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BODY HEIGHT; BODY WEIGHT; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION; REGRESSION ANALYSIS; SEX FACTORS; TRIAZOLES;

EID: 0031847284     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050808     Document Type: Article

References (12)

1. Beal SL, Sheiner LB (1982) Estimating population kinetics. CRC Crit Rev Biomed Eng 8: 195
2. Gibaldi M (1984) Biopharmaceutics and clinical pharmacokinetics, Lea & Fehiger, Philadelphia, p 209
3. Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York Basel
4. Haycock GB, Schwartz GJ, Wisotsky DH (1978) Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr 93: 62
5. Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M (1994) Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54: 5875
6. Maitre PO, Buhrer M, Thomson D, Stanski DR (1991) A three-step approach combining Bayesian regression and NONMEM population analysis - application to midazolam. J Pharmacokinet Biopharm 19: 377
7. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. 1. Models for covariate effects. J Pharmacokinet Biopharm 20: 511
8. MathSoft Inc. (1993) S-PLUS User's manual. MathSoft Inc., Seattle, Washington
9. Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage - implications for drug therapy. Clin Pharmacokinet 26: 292
10. Sheiner LB, Beal S (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503
11. Van Ginckel R, Janssens B, Callens M, Goeminne N, Wouters L, De Coster R (1996) Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7.12-dimethylbenz(a)anthracene-induced mammary carcinoma in the rat. Cancer Chemother Pharmacol 38: 21
12. Wouters W, Snoeck K, De Coster R (1994) Vorozole, a specific non-steroidal aromatase inhibitor. Breast Cancer Res Treatment 30: 89